Skip to content
Advertisement

A nurse, left, prepares a shot of AstraZeneca COVID-19 vaccine, manufactured by the Serum Institute of India and provided through the global COVAX initiative, from a portable cold storage box, center, in Machakos, Kenya, Wednesday, March 24, 2021. AstraZeneca's repeated missteps in reporting vaccine data coupled with a blood clot scare could do lasting damage to the credibility of a shot that is the linchpin in the global strategy to stop the coronavirus pandemic, potentially even undermining vaccine confidence more broadly, experts say. (AP Photo/Brian Inganga)

A nurse, left, prepares a shot of AstraZeneca COVID-19 vaccine, manufactured by the Serum Institute of India and provided through the global COVAX initiative, from a portable cold storage box, center, in Machakos, Kenya, Wednesday, March 24, 2021. AstraZeneca's repeated missteps in reporting vaccine data coupled with a blood clot scare could do lasting damage to the credibility of a shot that is the linchpin in the global strategy to stop the coronavirus pandemic, potentially even undermining vaccine confidence more broadly, experts say. (AP Photo/Brian Inganga)

Featured Photo Galleries